| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198367 | Journal of Allergy and Clinical Immunology | 2012 | 18 Pages |
Abstract
IGHy was effective, safe, and pharmacokinetically equivalent to IGIV at the same administration intervals, but it caused fewer systemic reactions. Tolerability was good despite high infusion volumes and rates.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Richard L. MD, PhD, Isaac MD, Mark R. MD, Sudhir MD, PhD, Jennifer MD, Werner PhD, Heinz PhD, Barbara PhD, Victoria G. MSc (Hons), David MD, Richard I. MD, PhD, IGSC, 10% with rHuPH20 Study Group IGSC, 10% with rHuPH20 Study Group,